Geode Capital Management
GLUE icon

Geode Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Geode Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4M Buy
1,540,812
+335,968
+28% +$6.42M ﹤0.01% 1870
2025
Q4 		$18.9M Buy
1,204,844
+53,278
+5% +$718K ﹤0.01% 2037
2025
Q3 		$8.53M Buy
1,151,566
+27,406
+2% +$145K ﹤0.01% 2503
2025
Q2 		$5.07M Buy
1,124,160
+120,098
+12% +$536K ﹤0.01% 2721
2025
Q1 		$4.66M Sell
1,004,062
-32,603
-3% -$200K ﹤0.01% 2688
2024
Q4 		$7.2M Sell
1,036,665
-8,024
-0.8% -$60.2K ﹤0.01% 2551
2024
Q3 		$5.54M Buy
1,044,689
+197,247
+23% +$996K ﹤0.01% 2706
2024
Q2 		$3.17M Buy
847,442
+111,909
+15% +$571K ﹤0.01% 2958
2024
Q1 		$5.19M Buy
735,533
+47,862
+7% +$284K ﹤0.01% 2684
2023
Q4 		$3.89M Buy
687,671
+40,183
+6% +$158K ﹤0.01% 2831
2023
Q3 		$3.1M Buy
647,488
+34,257
+6% +$221K ﹤0.01% 2883
2023
Q2 		$4.2M Buy
613,231
+30,142
+5% +$195K ﹤0.01% 2782
2023
Q1 		$4.54M Buy
583,089
+19,742
+4% +$137K ﹤0.01% 2676
2022
Q4 		$4.29M Buy
563,347
+33,235
+6% +$277K ﹤0.01% 2744
2022
Q3 		$4.33M Buy
530,112
+152,109
+40% +$1.4M ﹤0.01% 2751
2022
Q2 		$3.65M Buy
378,003
+20,328
+6% +$204K ﹤0.01% 2868
2022
Q1 		$5.01M Buy
357,675
+141,674
+66% +$1.97M ﹤0.01% 2799
2021
Q4 		$4.41M Buy
216,001
+20,218
+10% +$423K ﹤0.01% 2962
2021
Q3 		$4.36M Buy
+195,783
New +$5.61M ﹤0.01% 2989

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Geode Capital Management's GLUE Position: Q1 2026 in Review

Geode Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 28% in Q1 2026, buying an estimated $6.42M and bringing the position to 1,540,812 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

Geode Capital Management first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Geode Capital Management held 1,540,812 shares of Monte Rosa Therapeutics worth $25.4M as of Q1 2026.
  • Geode Capital Management bought 335,968 Monte Rosa Therapeutics shares in Q1 2026, an estimated $6.42M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1870 holding.
  • Geode Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.